OptimizeRx Q3 revenue $16.3M (+8% YoY); raises 2023 guidance, introduces 2024 outlook

OptimizeRx Corp

2023-Q3 EPS reported -$0.79 revenue$43,152,560

GAAP net loss per share $(0.17); non-GAAP EPS $0.09 vs $0.07 YoY.
2023 revenue guidance raised to $68-70M; adjusted EBITDA $3-4M.
Preliminary 2024 revenue guidance of at least $110M; adjusted EBITDA margin at least 10%.
Completed acquisition of Medicx Health post-Q3; total DAAP deals now at 16 for 2023.
Cash and investments $63.5M as of Sep 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OptimizeRx Corp reported full year 2023 results: revenue $68 million to $70 million. Guidance raised.

Period: full year 2023
Revenue: $68 million to $70 million
Guidance: raised
Result: guidance update

Exact text from the filing

we’re increasing our guidance for 2023 and are now looking for revenue and adjusted EBITDA to come in between $68-$70 million and $3-$4 million, respectively, for the year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

OptimizeRx Corp reported third quarter ended September 30, 2023 results: net income $(2.9) million, EPS $(0.17).

Period: third quarter ended September 30, 2023
Net income: $(2.9) million
EPS: $(0.17)
Result: reported results

Exact text from the filing

● Revenue in the third quarter of 2023 increased 8% to $16.3 million, as compared to $15.1 million in the same year ago period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

OptimizeRx Corp reported third quarter ended September 30, 2023 results: net income $(2.9) million, EPS $(0.17).

Period: third quarter ended September 30, 2023
Net income: $(2.9) million
EPS: $(0.17)
Result: reported results

Exact text from the filing

● GAAP net loss totaled $(2.9) million or $(0.17) per basic and diluted shares outstanding in the third quarter, as compared to $(3.5) million or $(0.19) during the third quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

OptimizeRx Corp reported 2024 results: revenue at least $110 million. Guidance initiated.

Period: 2024
Revenue: at least $110 million
Guidance: initiated
Result: guidance update

Exact text from the filing

We’re also introducing preliminary 2024 guidance and expect revenue to be at least $110 million and expect adjusted EBITDA margins to be at least 10%.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-083645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.